GLYCEMICON

Glycemicon AG is a Swiss biotechnology company developing novel nutraceuticals for managing prediabetes, diabetes and obesity, using new approaches that were initially developed at the University of Science & Technology ETH Zurich. The lead product’s active substance is a naturally-occurring bile acid, THBA, which drives changes to the body fat architecture that combat elevated blood glucose levels. Glycemicon stands for "glycemic control" - the maintenance of healthy blood sugar levels, which is the aim of every individual living with prediabetes and diabetes.